Sunday , 9 February 2025
Health

Bain Capital’s buyout of Mitsubishi Tanabe Pharma brings a company with a drug portfolio and pipeline in areas such as immunology, central nervous system disorders, and metabolic disease. This business is the pharmaceuticals division of Japanese conglomerate Mitsubishi Chemical Group.

The post Bain Capital Broadens Its Biotech Reach With $3.3B Deal for Mitsubishi Tanabe Pharma appeared first on MedCity News.

Leave a comment

Leave a Reply

Your email address will not be published. Required fields are marked *

Related Articles

Paths forward for accountable care. Value of continuity in primary care. CDC...

This analysis highlights USAID's role in global health and shows that the...

It’s time to replace this system with one that works for patients...

This brief considers options under consideration to cut Medicaid spending by $2.3...